The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis

Rheumatology International

Volumn 26, Issue 2, 2005, Pages 137-141

  Hein, Gert E ^a   Köhler, Markus ^a   Oelzner, Peter ^a   Stein, Günter ^a   Franke, Sybille ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Advanced glycation end products; Inflammatory markers; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL RECEPTOR; CYTOKINE; EPITOPE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PENTOSIDINE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLOOD LEVEL; BONE DESTRUCTION; BONE RADIOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SERUM; SYNOVIAL FLUID;

ARGININE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERLEUKIN-6; LYSINE; MALE; MIDDLE AGED; RECEPTORS, CYTOKINE; RHEUMATOID FACTOR; RHEUMATOLOGY; SYNOVIAL FLUID;

EID: 28844485738     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0518-1     Document Type: Article

References (38)

1. Zvaifler NJ, Firestein GS (1994) Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 37:783-789
2. Kinne RW, Palombo-Kinne E, Emmrich F (1995) Activation of synovial fibroblasts in rheumatoid arthritis. Ann Rheum Dis 54:501-504
3. Panayi GS, Lanchbury JS, Kingsley GH (1992) The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 35:729-734
4. Fox DA (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 40:598-609
5. Edmonds SE, Ellis G, Gaffney K, Archer J, Blake DR (1995) Hypoxia and the rheumatoid joint: immunological and therapeutic implications. Scand J Rheumatol 24 [Suppl 101]:163-168
6. Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87-101
7. Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436-443
8. Hofmann MA, Schiekofer S, Isermann B, Treusch A, Kanitz M, Klevesath MS, Joswing M, Morcos M, Weiss T, Borcea V, Khalet AM, Amiral J, Tritschler H, Wahl P, Ziegler R, Ritz E, Bierhaus A, Nawroth P (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrated increased activation of the oxidative-stress sensitive transcription NF-κB. Diabetologia 42:222-232
9. Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, Simm A (2001) Advanced glycation end products: activator of cardiac remodeling in primary fibroblasts from adult rat heart. Mol Med 7:543-551
10. Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T (1997) Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 36:637-642
11. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244:45-49
12. Drinda S, Franke S, Canet CC, Petrow P, Bräuer R, Hüttich C, Stein G, Hein G (2002) Identification of Ne-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 61:488-492
13. Drinda S Franke S, Rüster M, Petrow P, Pullig O, Stein G, Hein G (2004) Identification of the receptor of AGE (advanced glycation end products) in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int (accepted for publication)
14. Hein G, Wiegand R, Lehmann G, Stein G, Franke S (2003) Advanced glycation end-products pentosidine and Ne-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42:1242-1246
15. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomie S (1997) Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260-270
16. Hein G, Franke S (2002) Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41:1163-1167
17. Miyata T, Ueda Y, Shinzato T et al (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206
18. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implication for the induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Atheroscler Thromb 14:1521-1528
19. Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R (1999) Nonenzymatic glycation and oxidative stress in chronic diseases and diabetes mellitus [German]. Med Klin 94:29-38
20. Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia and tissue destruction. Arthritis Res 3:200-206
21. Handel ML, McMorrow LB, Gravallese EM (1995) Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38:1762-1770
22. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM (2000) Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 165:7199-7206
23. Yoshida S, Kato T, Sakurada S et al (1999) Inhibition of IL-6 and IL-8 from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151-158
24. Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483-1493
25. Tomita T, Takano H, Tomota N et al (2000) Transcription factor decoy for NFkB inhibits cytokine and adhesion molecule expression in synovial cells derived from rheumatoid arthritis. Rheumatology 39:749-757
26. Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253-259
27. Li P, Sanz I, O'Keefe RJ, Schwarz EM (2000) NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 164:5990-5997
28. Bond M, Baker AH, Newby AC (1999) Nuclear factor kappa B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 264:561-567
29. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-253
30. Takagi M, Kasayama S, Yamamoto T et al (1997) Advanced glycation endproducts stimulate interleukin-6 production by human bone derived cells. J Bone Miner Res 12:439-446
31. Yang C, Acil Y, Muller PK (1994) An unique antigenic determinant on collagen II closely associated with age related abnormal modification. Biochem Biophys Res Commun 16:1641-1649
32. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R (1994) T cell recognition of carbohydrates on type II collagen. J Exp Med 180:745-749
33. Charriere G, Hartmann DJ, Vignon E, Ronziere MC, Herbage D, Ville G (1988) Antibodies to types I, II, IX and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum 31:325-332
34. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 39:1720-1727
35. Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M, Fujii K, Sagara M, Kobayashi S, Goto M et al (1990) Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 33:1493-1500
36. Wooley PH, Luthra HS, Singh SK, Huse AR, Stuart JM, David CS (1984) Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc 59:737-743
37. Tai AW, Newkirk MM (2000) An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 120:188-193
38. Ligier S, Fortin PR, Newkirk MM (1998) A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol 37:1307-1314